Clinical trial · Interventional
Mechlorethamine Induced Contact Dermatitis Avoidance Study
Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study)
NCT03380026CI-TRIAL-00125846MIDAScompletedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a two-arm, open-label study that aims to compare the incidence and severity of the most common adverse reactions, particularly contact dermatitis, when Valchlor is used alone or in conjunction with triamcinolone ointment 0.1% in early stage MF subjects (Stage IA and IB) for a period of 4 months.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cutaneous T-cell Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | ALIAS | 0.90 |
| Cutaneous T-cell Lymphoma Stage I | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | CURATED_BROADER | 0.78 |
| Folliculotropic Mycosis Fungoides | Folliculotropic Mycosis Fungoides | ONTOLOGY_EXACT | 0.98 |
| Granulomatous Slack Skin | — | UNRESOLVED | — |
| Mycosis Fungoides | Mycosis Fungoides | ONTOLOGY_EXACT | 0.98 |
| Mycosis Fungoides Variant | Mycosis Fungoides Variant | ONTOLOGY_EXACT | 0.98 |
| Syringotropic Mycosis Fungoides | — | UNRESOLVED | — |
| Transformed Mycosis Fungoides | Transformed Mycosis Fungoides | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Triamcinolone | Drug | — | UNRESOLVED |
| Valchlor 0.016 % Topical Gel | Drug | Mechlorethamine | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Valchlor 0.016% Topical Gel
- description
- 0.016% w/w topical mechlorethamine gel applied over a minimum of 8 cm2, nightly, over a period of 4 months.
- interventionNames
- Drug: Valchlor 0.016 % Topical Gel
- type
- ACTIVE_COMPARATOR
- label
- Valchlor plus Triamcinolone
- description
- 0.016% w/w topical mechlorethamine gel (once, nightly) and Triamcinolone acetonide 0.1% ointment (up to three times daily) applied in over a minimum of 8 cm2, over a period of 4 months.
- interventionNames
- Drug: Triamcinolone
- Drug: Valchlor 0.016 % Topical Gel
Primary outcomes (1)
- measure
- Incidence of Moderate to Severe Contact Dermatitis by SCORD Scoring
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Be eligible to receive Valchlor therapy. * Be at least of 18 years of age and ability to give informed consent * Have stage IA or IB CTCL * Subjects with histologic variants of Mycosis Fungoides such as folliculotropic, granulomatous slack skin, syringotropic MF, or large cell transformation ARE eligible. * A skin biopsy within the last 60 days before start of treatment. In cases with equivocal histological features, the diagnosis may be confirmed with clinicopathologic and/or genetic testing consistent with the National Comprehensive Cancer Network guidelines for Mycosis Fungoides. If sufficient tissue is not available to perform genetic testing, a new biopsy will be performed even if the subject has had a biopsy within 60 days of start of treatment. * Females of child bearing potential must agree to use two highly effective methods of contraception (strongly recommended that one of the two forms of contraception be non-hormonal such as condom plus spermicide, condom plus diaphragm with spermicide, or have a vasectomized partner) or use an intrauterine device until 30 days after the last day of drug administration. Perimenopausal women must be amenorrhoeic for at least 12 months to be considered of nonchildbearing potential. * Males with female partners of child bearing potential must agree to sexual abstinence or use two reliable forms of effective contraception simultaneously (strongly recommended that one of the two forms should be non-hormonal as described above) during the entire treatment period and 30 days after the last dose. * Must be able to comply with the study instructions, apply the study medication as directed, and attend all visits. * Willingness to avoid sun exposure and ultraviolet B light in areas to be treated. Exclusion Criteria: * Have been treated with topical mechlorethamine within 6 months in lesions followed during this study. * Have received any topical therapy directed against MF within 2 weeks of start of treatment in areas intended to be treated in this study. * Have received any systemic therapy (oral or injectables) within 3 weeks of start of treatment. * Not have any intercurrent illness or infection that would interfere with study participation * Known hypersensitivity to mechlorethamine or triamcinolone. * Breastfeeding, pregnancy, or intention to become pregnant.
References
Publications (2)
- BACKGROUNDLessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013 Jan;149(1):25-32. doi: 10.1001/2013.jamadermatol.541. PMID 23069814
- DERIVEDAlexander-Savino CV, Chung CG, Gilmore ES, Carroll SM, Poligone B. Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides. Dermatol Ther (Heidelb). 2022 Mar;12(3):643-654. doi: 10.1007/s13555-022-00681-6. Epub 2022 Feb 5. PMID 35122614